

**Supplementary Table 2.** Characteristics of 588 BD Patients Based on the 1990 ISG Criteria

Variables	Values
At diagnosis	
Demographic data	
Age at diagnosis (yr)	39.0 (15.0)
Male sex	172 (29.3)
ANCA positivity at diagnosis	
MPO-ANCA (or P-ANCA)	8 (1.4)
PR3-ANCA (or C-ANCA)	5 (0.9)
MPO-ANCA (or P-ANCA) and PR3-ANCA (or C-ANCA)	0 (0)
ANCA negative	575 (97.8)
Clinical manifestation at diagnosis	
Oral ulcer	588 (100)
Genital ulcer	498 (84.7)
Ocular manifestation	299 (50.9)
Skin manifestation	530 (90.1)
Neurologic manifestation	38 (6.5)
Vascular manifestation	26 (4.4)
Pathergy test positivity	11 (1.9)
Comorbidities at diagnosis	
Diabetes mellitus	53 (9.0)
Hypertension	85 (14.5)
Dyslipidemia	83 (14.1)
Aortic valve replacement	5 (0.9)
Percutaneous coronary intervention	10 (1.7)
Other vascular Intervention	11 (1.9)
During follow-up	
Poor outcomes during follow-up	
All-cause mortality	2 (0.3)
CVA	27 (4.6)
ACS	25 (4.3)
DVT	21 (3.6)
GI involvement	76 (12.9)
Ocular involvement	37 (6.3)
Medications administered during follow-up	
Glucocorticoid	471 (80.1)
Colchicine	454 (77.2)
Azathioprine	144 (24.5)
Methotrexate	33 (5.6)
Cyclosporine	21 (3.6)
TNF- $\alpha$ blockade	9 (1.5)

BD, Behçet's disease; ISG, International Study Group; ANCA, antineutrophil cytoplasmic antibody; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; CVA, cerebrovascular accident; ACS, acute coronary syndrome; DVT, deep vein thrombosis; GI, gastrointestinal; TNF, tumor necrosis factor.

Values are expressed as a median (interquartile range, IQR) and number (percentage).